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Abstract
Background:  Toxoplasmosis is an infectious disease caused by the parasitic protozoan
Toxoplasma gondii. It is endemic worldwide and, depending on the geographic location, 15 to 85%
of the human population are asymptomatically infected. Routine diagnosis is based on serology. The
parasite has emerged as a major opportunistic pathogen for immunocompromised patients, in
whom it can cause life-threatening disease. Moreover, when a pregnant woman develops a primary
Toxoplasma gondii infection, the parasite may be transmitted to the fetus and cause serious
damnage. For these two subpopulations, a rapid and accurate diagnosis is required to initiate
treatment. Serological diagnosis of active infection is unreliable because reactivation is not always
accompanied by changes in antibody levels, and the presence of IgM does not necessarily indicate
recent infection. Application of quantitative PCR has evolved as a sensitive, specific, and rapid
method for the detection of Toxoplasma gondii DNA in amniotic fluid, blood, tissue samples, and
cerebrospinal fluid.
Methods: Two separate, real-time fluorescence PCR assays were designed and evaluated with
clinical samples. The first, targeting the 35-fold repeated B1 gene, and a second, targeting a newly
described multicopy genomic fragment of Toxoplasma gondii. Amplicons of different intragenic
copies were analyzed for sequence heterogeneity.
Results:  Comparative LightCycler experiments were conducted with a dilution series of
Toxoplasma gondii genomic DNA, 5 reference strains, and 51 Toxoplasma gondii-positive amniotic
fluid samples revealing a 10 to 100-fold higher sensitivity for the PCR assay targeting the newly
described 529-bp repeat element of Toxoplasma gondii.
Conclusion: We have developed a quantitative LightCycler PCR protocol which offer rapid
cycling with real-time, sequence-specific detection of amplicons. Results of quantitative PCR
demonstrate that the 529-bp repeat element is repeated more than 300-fold in the genome of
Toxoplasma gondii. Since individual intragenic copies of the target are conserved on sequence level,
the high copy number leads to an ultimate level of analytical sensitivity in routine practice. This
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newly described 529-bp repeat element should be preferred to less repeated or more divergent
target sequences in order to improve the sensitivity of PCR tests for the diagnosis of
toxoplasmosis.
Background
Toxoplasmosis is an infectious disease caused by the pro-
tozoan Toxoplasma gondii effecting individuals throughout
the world. Two main subpopulations are highly suscepti-
ble to this parasite: the fetus and an immunocompro-
mised individual. Congenital infection may induce
spontaneous abortion or serious sequelae when maternal
infection occurs during pregnancy. Both the damage for
the fetus (the sooner, the more deleterious) and the fre-
quency of trans-placental transmission (the later, the
more frequent) is usually depending on the stage of gesta-
tion. In the immunocompromised host, the prognosis for
cerebral disseminated toxoplasmosis is poor, with a mor-
tality rate of 63% [1]. For these two subpopulations, a rap-
id and accurate diagnosis is required to initiate treatment.
Diagnosis with radiological findings, histology, tissue cul-
ture, or inoculation into mice is difficult, time consuming,
or impractical. Since anti-toxoplasma antibody titers are
often unchanged or decreased at the onset of clinical
symptoms, and most cases of active toxoplasmosis are due
to reactivation of latent infection, the serological status is
solely useful in order to know whether the patient is at risk
for reactivation. This is why the direct demonstration of
the parasite in tissues or other biological fluids by PCR is
a major breakthrough for the diagnosis of toxoplasmosis
in these patients [2,3].
The reliability of the detection of T. gondii DNA in amni-
otic fluids (AF) or blood is of utmost importance. Real-
time PCR assays have recently emerged as a dramatic im-
provement in the reliability of PCR assays. Since the reac-
tion tubes need not be opened after amplification,
avoiding potential contamination of the environment
with amplicons, the risk of false positive results are dra-
matically reduced. Quantitative PCR also provides addi-
tional data to direct the choice of specific treatments [4].
Real-time PCR also provides the opportunity to compare
the sensitivity of different DNA targets. Several studies re-
port a relatively high level of false negative results in pre-
natal diagnosis [5] or huge differences between
immunocompromised patients using current PCR assays
[6,7]. This may be due to pathophysiological reasons, ex-
plaining the absence or intermittent presence of the para-
site in the specimens tested, or by poor performance of the
PCR assays. The use of more repetitive but not polymor-
phic DNA targets may help to resolve this issue.
We have developed a real-time PCR assay targeting a re-
cently discovered repetitive 529-bp DNA fragment in T.
gondii [8], and compared the results to our previously de-
veloped PCR assay targeted to the multicopy gene B1 [9].
Whereas the number of B1 gene copies has been estimated
around 35, the number of repeats of the 529-bp DNA frag-
ment is reported to be between 230 and 330 [8]. We com-
pared the sensitivity our two LightCycler (LC) PCR assays
with serial dilutions of T. gondii DNA and subsequently
analyzed amniotic fluids to compare the efficiency of the
two PCR protocols.
Methods
T. gondii isolates, clinical samples and bacterial strains
Five reference strains of T. gondii, including the RH strain,
two of zymodeme 1, two of zymodeme 2, one of zymo-
deme 3 [10], and seven strains derived from human am-
niotic fluids (AF), were selected from the culture
collections of our institutions. DNA preparations from 51
amniotic fluid samples, which were received by the Hôpi-
tal américain de Paris between 1996 to 2001 and tested T.
gondii  positive using a previously published PCR assay
[11], were used as PCR templates. In addition, 160 clinical
specimens of various types originating from patients with-
out a suspected T. gondii infection (about 50 % of these
patients were seropositive for Toxoplasma but do not show
clinical symptoms of acute disease), and 118 strains from
different bacterial genera, were included in the study.
Template DNA preparation
Genomic DNA of T. gondii strains was prepared as
desribed previously [11]. Template DNA from clinical
specimens was prepared using the High Pure PCR Tem-
plate Preparation kit (Roche Diagnostics, Mannheim,
Germany) according to the manufacturer's instructions.
Following the centrifugation and washing steps, total
DNA was eluted from the spin columns with 100 µl of elu-
tion buffer, and 5 µl aliquots were directly transferred to a
PCR reaction.
Nucleotide sequence analysis of the cryptic T. gondii tar-
get
To identify potential sequence variations within the target
sequence among different T. gondii strains, or among dif-
ferent copies of the gene within the chromosome of one
organism, total genomic DNA of 5 reference strains and 7
clinical isolates were amplified using primer Tox-8 (5'-
CCC AGC TGC GTC TGT CGG GAT-3') and primer Tox-5
(5'-GAC GTC TGT GTC ACG TAG ACC TAA G-3'). SpecificBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/7
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amplification products of 450-bp were purified using the
HighPure PCR Product Purification kit (Roche Diagnos-
tics), and cycle sequencing reactions were performed as
described in the PRISM Ready Reaction Dye Deoxy Termi-
nator cycle sequencing kit protocol (Applied Biosystems,
Weiterstadt, Gemany). Both strands of amplicons origi-
nating from different amplification reactions were se-
quenced in duplicate to rule out the possibility of Taq
DNA polymerase-induced errors. Optimal results were
obtained using amplification primers Tox-8 and Tox-5 as
forward and reverse sequencing primers, respectively. The
fluorescent-labeled reaction products were analyzed with
a ABI PRISM 310 Genetic Analyzer (Applied Biosystems).
Primer and hybridization probe design
One LC-PCR assay, which was described in detail previ-
ously, targeted the B1 gene of T. gondii [4,11]. The other
LC-PCR assay targeted a recently described T. gondii 529-
bp DNA repeat element of cryptic function. Based on the
newly determined consensus sequence GenBank
AF487550, two primer oligonucleotides were selected
flanking a conserved 162-bp region within the T. gondii-
specific repeat element. For the sequence-specific detec-
tion of the corresponding amplicons, a pair of LightCycler
hybridization probes were designed against sequences in-
ternal to the amplified region. The nucleotide sequences
of primers and hybridization probes and their corre-
sponding locations within GenBank AF487550 are shown
in Table 1.
LC-PCR assays and product detection
DNA oligonucleotide primers and hybridization probes
were synthesized by TIB Molbiol, Berlin, Germany. All LC-
PCR assays were performed using a fluorescence detecting
temperature cycler (LightCycler; Roche Diagnostics). The
amplification mixture consisted of 2 µl of 10 X reaction
mix (LightCycler FastStart Master Hybridization Probes,
Roche Diagnostics), 4 mM MgCl2, 0.5 µM of each oligo-
nucleotide primer, 0.25 µM of each oligonucleotide
probe, and 5 µl of template DNA in a final volume of 20
µl. Carry-over was prevented by using the heat-labile ura-
cyl-DNA-glycosylase (UNG) (Roche Diagnostics). The re-
action mixture was initially incubated for 1 min at room
temperature to allow the UNG to act. This incubation was
followed by a 10-min incubation step at 95°C to denature
the template DNA, to inactivate the UNG enzyme, and to
activate the Fast Start Taq DNA polymerase. Samples were
amplified as follows: 50 cycles of denaturation at 95°C for
10 sec, annealing at 56°C for 20 sec, and an extension at
72°C for 20 sec. The temperature transition rate was
20°C/sec.
The generation of target amplicons for each sample was
monitored between the annealing and the elongation
steps at 640 nm. Samples positive for target genes were
identified by the instrument at the cycle number where
the fluorescence attributable to the target sequences ex-
ceeded that measured for background. Those scored as
positive by the instrument were confirmed by visual in-
spection of the graphical plot (cycle number versus fluo-
rescence value) generated by the instrument.
Quantification of LightCycler products
The quantitative interpretation of LightCycler results was
assisted by the "fit point method" algorithm with the
"minimize error" option (LightCycler software Vers. 3.5;
Roche Diagnostics). The LightCycler software performs all
additional calculation steps necessary for generation of a
standard curve. Briefly, a noise band (treshold) is auto-
matically set at a fluorescence level, at which the fluores-
cence signal development reflects that the PCR is in the
log-linear phase. The software then calculates the logarith-
mic values by interpolating a straight line through 2 data
points above the treshold value, and the points of
intersection (crossing points) with the noise band are de-
termined. Finally, the crossing points are plotted against
the logarithm of the target DNA concentration in individ-
ual samples.
Sensitivity of the LC-PCR assays for T. gondii detection
To assess the the analytical sensitivity of the PCR assays for
the two different target genes, 10-fold serial dilutions of T.
gondii DNA (RH strain) were prepared, ranging from 2 ng
to 2 fg input per 20 µl PCR reaction. On the assumption
that one 80-Mbp genome equivalent of T. gondii equals
about 80 fg, this would be 2.5 × 104 down to 2.5 × 10-2
Table 1: Oligonucleotide primers and LightCycler hybridization probes used in the PCR assay.
Oligo-nucleotide Sequence a





Tox-9 AGG AGA GAT ATC AGG ACT GTA G Cryptic 143–164 AF487550 Present study
Tox-11 GCG TCG TCT CGT CTA GAT CG Cryptic 304–285 AF487550 Present study
Tox-HP-1 GAG TCG GAG AGG GAG AAG ATG TT-[FL] Cryptic 214–236 AF487550 Present study
Tox-HP-2 [Red 640]-CCG GCT TGG CTG CTT TTC CTG-Ph Cryptic 238–258 AF487550 Present study
a [FL], fluorescein; [Red 640], LightCycler-Red 640-N-hydroxy-succinimide ester; [Ph], 3'-phosphate.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/7
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parasite equivalents. The dilution series were tested in
triplicate with the two LC-PCR assays to determine the
minimum amount of template DNA per reaction that
could be detected by each protocol.
Results
Sequencing of T. gondii reference strains
Sequencing plots obtained with the amplicons originating
from the five reference strains and the seven clinical iso-
lates of T. gondii were clearly interpretable. An alignment
of the 404-bp region flanked by primers Tox-8 and Tox-5
showed complete homology between the nucleotide se-
quences among the investigated strains. Compared to
GenBank AF146527, some divergent nucleotide positions
were observed. Briefly, an "A" to "G" substitution was
identified at pos. 160, a "C" to "T" substitution at pos.
391, and a "G" to "C" substitution at pos. 495. An ambig-
uous "S" nucleotide position was consistently observed at
pos. 275, which indicated the presence of either "G" or
"C" nucleotides within different copies of the 529-bp frag-
ment in the genome of T. gondii. At pos. 367 the deletion
of an "A" nucleotide was consistently observed with all se-
quenced isolates of T. gondii. The nucleotide sequence of
the newly determined 404-bp partial sequence within the
T. gondii 529-bp repeat region was deposited in GenBank
under accession number AF487550.
Direct sequencing of amplicons generated with 51 T. gon-
dii-positive human amniotic fluid samples revealed com-
plete homology to the newly determined GenBank
AF487550, and all of the variant nucleotide positions
with respect to GenBank AF146527 were confirmed.
Comparison of analytical sensitivity for the two targets
When the B1-specific set of LightCycler PCR primers and
hybridization probes were applied to the 10-fold dilution
series of T. gondii genomic DNA, a detection limit of 200
fg was consistently observed after 35 cycles of amplifica-
tion. As expected, this level of analytical sensitivity was in
agreement with previous reports [4,11].
When the set of LightCycler PCR primers and hybridiza-
tion probes specific for the T. gondii 529-bp repeat ele-
ment was applied to an identical dilution series of
template DNA, a detection limit of about 20 fg of T. gondii
genomic DNA was consistently observed after 35 cycles of
amplification. Graphs depicting the accumulation of flu-
orescence throughout the PCR assays for the B1 gene and
the 529-bp repeat element with 10-fold dilution series of
genomic DNA are shown in Figures 1 and 2.
For a given starting concentration of template DNA
present in individual reaction mixtures, the quantitative
PCR results expressed in crossing points (Cp) were about
3.5 cycles earlier with the 529-bp repeat element LC assay
than with the B1 gene LC assay. From the slope of the cal-
culated standard curve, the efficiency of the underlying
amplification process (10-1/slope) was calcultated as 1.84
for both the B1 gene (Figure 1) and the 529-bp repeat el-
ement (Figure 2). This value was near to the theoretical
optimum of 2, and indicated an optimal course of the am-
plification process leading to precise and reproducible
quantitative results. Based on the principle of quantitative
PCR, N = N0 × En (where N is the actual number of ampli-
cons present in the reaction mixture after n cycles, N0 is
the initial number of template molecules, and E is the ef-
ficiency of the amplification process), a difference of 3.5
crossing points for a given starting concentration of tem-
plate DNA equals a tenfold higher concentration of am-
plicons in the reaction mixture for the 529-bp repeat
element during the logarithmic phase of amplification.
Considering the identical amplification efficiencies ob-
served for both LC protocols, it was a clear indication that
the actual number of 529-bp repeat elements within the
genome of T. gondii is at least tenfold higher than the 35-
fold repeated B1 gene. Comparative LC experiments on a
collection of 51 T. gondii-positive human amniotic fluids
showed a gain in Cp of 4.6 +/- 1.1 cycles (range 2.4–6.9)
for the assay targeting the 529-bp repeat element (Figure
3). These results obtained with clinical specimens were in
agreement with the above mentioned findings on the di-
lution series of T. gondii genomic DNA.
Specificity of the LC assays
The specificity of the LC assay targeting the B1 gene of T.
gondii has been investigated before [4,11]. The analytical
specificity of the LC assay targeting the 529-bp-repeat ele-
ment was evaluated by testing DNA preparations from 5
reference strains and 7 clinical strains of T. gondii. In addi-
tion, DNA preparations from 51 T. gondii-positive amni-
otic fluids, 160 T. gondii-negative clinical specimens, and
118 strains of diverse clinically relevant bacterial species
were included in the study. With all of the 62 T. gondii-
positive DNA preparations, clearly positve results were
obtained from the LightCycler amplification screen and a
specific Tm of 65°C was consistently observed upon melt-
ing curve analysis. DNA preparations from 160 clinical
specimens, originating from patients without a suspected
T. gondii infection, as well as from 118 strains of different
bacterial genera, remained negative from the LightCycler
amplification screen and in melting curve analysis. No
cross-reactions or borderline results from high amounts of
human chromosomal DNA were observed. The specifici-
ty, and the predictive value of the LC-PCR assay targeting
the 529-bp repeat element were each 100%.
Discussion
As for all parasitic diseases, the PCR diagnosis of toxoplas-
mosis is not standardized. It seems highly probable that
there will be a consensus on real-time PCR assays in theBMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/7
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next few years [4,11,12]. However, the consensus on the
best sequence to be amplified will be more difficult. The
findings of our study clearly confirm that the recently de-
scribed 529-bp DNA fragment is present in much higher
copy number than the 35-fold repeated B1 gene [8], and
is highly conserved on a nucleotide sequence level
between strains and isolates. Therefore, this DNA target
offers an improvement in the sensitivity of PCR tests for
the detection of T. gondii DNA.
Figure 1
Quantitative analysis of LightCycler results obtained on 10-fold serial dilutions of T. gondii genomic DNA using 
the B1-specific PCR protocol. The corresponding template DNA concentrations, ranging from 2 ng to 0.2 pg input per 20 
µl PCR reaction, are indicated next to the amplicon curves. Based on the slope of the original amplification curves during the 
log-linear phase determined by two data points, artificial crossing points with the noise band (horizontal line) were determined 
by the LightCycler software (A). The standard curve represented the linear regression line through the data points on a plot of 
crossing points (threshold cycle) vs logarithm of standard sample concentration (B). Slope, Y-intercept, mean squared error, 
and regression coefficient of the standard curve are given.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/7
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Three repeated DNA sequences have been studied so far
for the diagnosis of toxoplasmosis. The rRNA genes have
been the basis for several independent PCR assays
[6,13,14] but the homogeneity of the amplified fragments
has never been demonstrated to a sufficient extent. That
may explain the observation of Jones et al. [15], who
found the 35-fold repeated B1 target more sensitive than
the ribosomal genes [14]. The TGR1E is a non-coding re-
petitive element of T. gondii, evaluated as a diagnostic tar-
get for PCR [16,17], but abandoned because of sequence
Figure 2
Quantitative analysis of LightCycler results obtained on 10-fold serial dilutions of T. gondii genomic DNA using 
the PCR protocol specific for the 529-bp repeat element. The corresponding template DNA concentrations, ranging 
from 2 ng to 20 fg input per 20 µl PCR reaction, are indicated next to the amplicon curves. Based on the slope of the original 
amplification curves during the log-linear phase determined by two data points, artificial crossing points with the noise band 
(horizontal line) were determined by the LightCycler software (A). The standard curve represented the linear regression line 
through the data points on a plot of crossing points (threshold cycle) vs logarithm of standard sample concentration (B). Slope, 
Y-intercept, mean squared error, and regression coefficient of the standard curve are given.BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/7
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heterogeneity among different copies of the repeated ele-
ments and the impossibility to find suitable PCR primers
for amplification [18]. Up till now, the most popular DNA
target for diagnosing toxoplasmosis was the B1 gene, with
a huge diversity of published primers and PCR protocols
[3,6,11,19–22]. Altough the heterogeneity of the B1 re-
peats is well known [23], it seems to be sufficiently con-
served for diagnostic purposes. However, the primers for
amplification must be carefully designed to amplify all
the different types of T. gondii. We have shown that most
of the T. gondii isolates in amniotic fluids are of type 2
[24], whereas most of the published PCR primers are de-
signed complementary to the type 1 sequences.
With respect to the recently described 529-bp repeat ele-
ment, the sequencing data indicate a highly conserved nu-
cleotide sequence among various strains and isolates of T.
gondii  and, equally important for hybridization probe-
based detection of amplicons, among different intragen-
omic copies of this particular target. Alignment of our se-
quencing results with 62 different T. gondii isolates (5
reference strains, 7 clinical isolates and 51 T. gondii-posi-
tive amniotic fluids) revealed 3 nucleotide mutations, one
deletion, and one defined nucleotide ambiguity com-
pared to GenBank AF146527. The newly determined 404-
bp partial sequence within the T. gondii 529-bp repeat re-
gion was deposited as GenBank AF487550.
Since the sequence of the original GenBank entry
AF146527 was obtained with cloned amplicons, only sin-
gle molecules of the 529-bp amplicons have been investi-
gated by Homan et al. [8]. Without doubt, this project was
an important step towards the molecular characterization
of the T. gondii-specific 529-bp repeat element. Knowing
about, and, as a consequence, omitting the extremely "T"-
rich region at the 3' end of the target gene, we used the
primer pair Tox-5 and Tox-8 for amplification and direct
sequencing of a 404-bp internal segment. This integrated
sequencing approach, in connection with the ABI four-
dye one-lane sequencing technology, led to a more de-
tailed insight into the nucleotide variations present at in-
dividual positions within different intragenomic copies of
the T. gondii 529-bp repeat element.
Based on the newly determined consensus sequence Gen-
Bank AF487550, we designed a set of LightCycler PCR
primers and hybridization probes specific for the T. gondii
529-bp repeat element. Compared to a well-established
Figure 3
Results of LightCycler experiments on 51 T. gondii-positive human amniotic fluids comparing the B1-specific 
PCR protocol and the PCR protocol specific for the 529-bp repeat element. Comparative LC PCR experiments 
were performed on DNA preparations of a collection of 51 T. gondii-positive human amniotic fluids. The real-time PCR assay 
targeting the 529-bp repeat element (red bars) showed a mean gain in LC crossing points of 4.6 with respect to the real-time 
PCR assay targeting the B1 gene (yellow bars). The diagram depicts the individual LC crossing points (x-axis) observed for each 
of the investigated amniotic fluid samples (y-axis).BMC Infectious Diseases 2003, 3 http://www.biomedcentral.com/1471-2334/3/7
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LC protocol targeting the B1 gene, the analytical sensitivi-
ty of the novel LC protocol was evaluated with 10-fold di-
lution series of T. gondii genomic DNA. Here a detection
limit of 20 fg of genomic DNA was consistently observed,
which was found to be ten times more sensitive than the
results obtained with the B1-specific LC assay.
Real-time PCR provides quantitative results, since the cy-
cle number in which amplicons become detectable is pro-
portional to the logarithm of initial number of templates.
Identical amplification efficiencies and the fact that a gain
in crossing point values of about 3.5 cycles was observed
with the 529-bp repeat element LC assay for a given start-
ing concentration of template DNA, the actual copy
number of 529-bp repeat elements within the genome of
T. gondii must be at least tenfold higher than the copy
number of the 35-fold repeated B1 gene. Statistical exploi-
tation of quantitative LightCycler results obtained with 51
T. gondii-positive human amniotic fluids showed a gain in
crossing point values of 4.6 in average, thereby supporting
the practical advantage of the 529-bp repeat element over
the B1 gene as diagnostic target with respect to assay
sensitivity.
With respect to the quantitative PCR protocol of Homan
et al. [8], who amplified the complete 529-bp repeat re-
gion and observed a detection limit of four tachyocytes,
we intentionally amplified only an internal 162-bp seg-
ment of the target gene, thereby omitting the extremely
"T"-rich region at the 3'-end. It is well known that long
stretches of identical nucleotides in the template strand
may cause a "stuttering" behaviour of the Taq  DNA
polymerase reducing the speed of the elongation process
or causing the enzme to fall off the template strand. Leav-
ing this problematic "T"-rich segment of the target gene
improved the efficiency of the amplification process and a
detection limit of less than one tachyzoite equivalent was
observed in the present study.
The specificity of the newly developed LC assay targeting
the the T. gondii 529-bp repeat element was evaluated
with DNA preparations of 62 T. gondii isolates or clinical
specimens positive for T. gondii, 160 clinical specimens
from patients without a suspected T. gondii infection, and
118 strains of different bacterial species. Positive PCR re-
sults were observed with only the 62 T. gondii-positive
DNA preparations whereas all of the other DNA prepara-
tions remained negative. No cross-reactions or borderline
PCR results in the presence of high amounts of human
chromosomal DNA were observed. Consistently negative
PCR results were observed with specimens of various
types originating from individuals who had anti-toxoplas-
ma antibodies but no clinical symptoms of acute
toxoplasmosis.
Although we evaluated the novel LC assay with a collec-
tion of T. gondii-positive amniotic fluid samples, other bi-
ological fluids like blood, aqueous humor, vitreous, or
tissues may also serve as starting material for the sensitive
detection of the parasites in clinical samples [25,26]. It
should be considered that the repartition of the toxoplas-
mosis cysts in organs, such as heart or brain, is not ho-
mogenous and the size of the sample subjected to DNA
extraction is a key issue. Consequently, a negative PCR re-
sult with a small biopsy section does not definitively ex-
clude the presence of toxoplasmosis cysts in a given organ
or clinical sample.
Conclusions
We have developed a quantitative T. gondii-specific Light-
Cycler protocol which offer rapid cycling (1 hour or less)
with real-time, sequence-specific detection of amplicons.
The fluorescent-labeled hybridization probes not only
provide confidence in the identification of the target se-
quence, but also reduce the risk of experiencing product
contamination of the laboratory since the amplification
reaction and the detection of PCR products are conducted
in a single capillary tube. From quantitative PCR it can be
concluded that the 529-bp repeat element of T. gondii [8]
is repeated more than 300-fold. Sequencing of PCR am-
plicons demonstrated a highly conserved nature of indi-
vidual intragenic copies of this multicopy gene. No
significant sequence homologies with other GenBank en-
tries were observed. This newly described target sequence
should be preferred to less repeated or more divergent tar-
get sequences in order to improve the sensitivity of the
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